Loading clinical trials...
Loading clinical trials...
EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS
Conditions
Interventions
In open-label phase: treatment with tofacitinib
In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio
Locations
52
United States
Phoenix Children's Hospital
Phoenix, Arizona, United States
Children's Hospital Los Angeles
Los Angeles, California, United States
Ann & Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
Cohen Children's Medical Center of New York
Lake Success, New York, United States
Cohen Children's Medical Center of New York
New Hyde Park, New York, United States
Instituto CAICI SRL
Rosario, Santa Fe Province, Argentina
Start Date
May 10, 2018
Primary Completion Date
March 27, 2024
Completion Date
March 27, 2024
Last Updated
June 3, 2025
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions